Unbiased AI-powered news
3 stories related to this topic, newest first.
cnbc.comThe temporary GLP-1 Bridge program will run through December 2027. Taxpayers will cover most costs for millions of new patients.
indiatoday.intoday.inMounjaro generated $8.7 billion in sales during the first quarter, surpassing Merck's Keytruda which recorded $7.9 billion. Keytruda had held the position of the world's best-selling drug since the beginning of 2023. The shift reflects changing revenue rankings among leading phar…
news18.comFrance's medicines regulator imposed fines on Novo Nordisk and Eli Lilly for misleading advertisements related to their weight loss drugs. The penalties come amid launches of oral GLP-1 medications in the U.S., with Novo Nordisk's Wegovy pill gaining early traction. Company execu…